Table 1.
Baseline patient characteristics
| PEG hydrogel placement (n = 51) | Controls (n = 21) | P Value | |
|---|---|---|---|
| Median age (IQR) | 73.9 (70.0-78.0) | 74.9 (73.0-78.05) | .291 |
| Median BMI (IQR) | 26.7 (4.8-30.1) | 26.3 (24.9-30.0) | .78 |
| Median PSA (ng/mL) (IQR) | 6.9 (4.5-10.2) | 9.7(4.8-12.4) | .222 |
| Patient on ADT | 26 (n = 40, 65%) | 19 (n = 10, 95%) | .027 |
| Gleason score | .361 | ||
| 3 + 3 | 10 (19.6%) | 1 (4.8%) | |
| 3 + 4 | 15 (29.4%) | 4 (19.0%) | |
| 4 + 3 | 15 (29.4%) | 8 (38.1%) | |
| 4 + 4 | 7 (13.7%) | 6 (28.6%) | |
| 4 + 5 | 2 (3.9%) | 2 (9.5%) | |
| 5 + 4 | 1 (2.0%) | 0 | |
| 5 + 5 | 1 (2.0%) | 0 | |
| Clinical stage | .65 | ||
| T1 (T1a, T1b, T2c) | 22 (43.1%) | 8 (38.1%) | |
| T2 | 24 (47.1%) | 12 (57.1%) | |
| T3 (T3a, T3b) | 5 (9.8%) | 1 (4.8%) | |
| Median radiation dose delivered Gy (IQR) | 79.2 (79.2-79.2) | 79.2 (79.2-79.2) | .621 |
| Median no. of fractions delivered | 44.0 (44.0-44.0) | 44.0 (44.0-44.0) | .786 |
Abbreviations: ADT = androgen deprivation therapy; BMI = body mass idex; IQR = interquartile ratio; PEG = polyethylene glycol; PSA = prostate-specific antigen.